Briacell Therapeutics Corp. Common Shares (BCTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCTX trades at $3.75 with a market cap of $24.29M and a P/E ratio of -0.06. BCTX moved +9.69% today. Year to date, BCTX is -49.28%; over the trailing twelve months it is -89.10%. Its 52-week range spans $2.98 to $214.50. Rallies surfaces BCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading BCTX stock inside the company?
Recent BCTX insider activity includes Lustig Marc bought 902.93K, Bondarenko Jamieson bought 28.00K, and Bondarenko Jamieson bought 22.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
BCTX Key Metrics
Key financial metrics for BCTX
Metric
Value
Price
$3.75
Market Cap
$24.29M
P/E Ratio
-0.06
EPS
$-62.19
Dividend Yield
0.00%
52-Week High
$214.50
52-Week Low
$2.98
Volume
6.53K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-26.56M
Gross Margin
0.00%
Recent BCTX Insider Trades
Lustig Marc bought 902.93K (~$2.00M) on May 14, 2024.
Bondarenko Jamieson bought 28.00K (~$128.24K) on Dec 28, 2022.
Bondarenko Jamieson bought 22.00K (~$117.70K) on Dec 20, 2022.
BCTX analyst coverage data. Average price target: $0.00.
Common questions about BCTX
Who is trading BCTX stock inside the company?
Recent BCTX insider activity includes Lustig Marc bought 902.93K, Bondarenko Jamieson bought 28.00K, and Bondarenko Jamieson bought 22.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BCTX?
Yes. Rallies tracks BCTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BCTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCTX. It does not provide personalized investment advice.
